Bioxcel therapeutics announces pricing of $7.0 million public offering

New haven, conn., nov. 22, 2024 (globe newswire) -- bioxcel therapeutics, inc. (the “company”) (nasdaq: btai), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced the pricing of an underwritten public offering of 5,600,000 shares of its common stock, par value $0.001 per share (“common stock”), and accompanying warrants to purchase up to 5,600,000 shares of common stock, and, in lieu thereof to certain investors that so choose, pre-funded warrants to purchase up to 9,000,000 shares of common stock and accompanying warrants to purchase up to 9,000,000 shares of common stock, at a combined public offering price of $0.48 per share and accompanying warrant (or $0.479 per share underlying each pre-funded warrant and accompanying warrant, which equals the public offering price per share of common stock and accompanying warrant less the $0.001 exercise price per share of the pre-funded warrants). gross proceeds to the company from the offering are expected to be approximately $7.0 million, before deducting underwriting discounts and commissions and offering expenses, and excluding the exercise of any of the warrants.
BTAI Ratings Summary
BTAI Quant Ranking